Mouse anti-CIP2A Monoclonal Antibody Affinity Purified [2A1-9A4]
Catalog #
CIP2A
Human
,Mouse
IP
,WB
Mouse
Monoclonal
2A1-9A4
Whole IgG
Amino terminal one-third of the CIP2A (GeneID 57650) recombinant protein
IgG1-kappa
Unconjugated
Purified
Product Details
Mouse,
Human
Human
Human
2 - 8 °C
1 year from date of receipt
Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide
Request Formulation Change
Tris-buffered Saline containing 0.09% Sodium Azide, BSA-Free
Request Formulation Change
The immunogen was the amino terminal one-third of the CIP2A (GeneID 57650) recombinant protein.
The hybridoma was grown in a bioreactor and the antibody was purified using a mouse immunoglobulin binding ligand.
USA
CIP2A (cancerous inhibitor of PP2A) was originally identified as p90, a cytoplasmic autoantigen found in the serum from a cancer patient. It was later described as a protein that interacted with the c-myc oncogene and functioned as an inhibitor of protein phosphatase 2A (PP2A) activity. Inhibition of PP2A phosphatase activity by CIP2A prevents c-myc phosphorylation and counteracts c-myc proteolytic degradation, thereby stabilizing c-myc and promoting cell growth and transformation. CIP2A is found to be overexpressed in some human malignancies and is thus classified as an oncogene that may be an important contributor to tumor formation.
Alternate Names
cancerous inhibitor of PP2A; cancerous inhibitor of protein phosphatase 2A; KIAA1524; p90; p90 autoantigen; protein CIP2A
Applications